Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDr. Martens Regulatory News (DOCS)

Share Price Information for Dr. Martens (DOCS)

Share Price is delayed by 15 minutes
Get Live Data
71.50    0.50 (0.70%)
Bid:
71.20
Ask:
74.00
Spread: 2.80 (3.933%)
Market Cap: £684.32m
DOCS Live PriceLast checked at - London Stock Exchange

Intraday Dr. Martens Share Chart

AGM Trading Update

10 Jul 2025 07:00

RNS Number : 4225Q
Dr. Martens PLC
10 July 2025
Β 

10 July 2025

Dr. Martens plc - AGM Trading Update

Trading in line with expectations; FY26 guidance unchanged

Β 

Dr. Martens plc will hold its AGM at 09.30am today at 1-11 Hawley Crescent, Camden, London, NW1 8NP, and also provides the following update.

Trading since the start of this financial year has been in line with expectations and all guidance for FY26 remains unchanged. On a regional basis, we have continued to see positive trading in our Americas Direct to Consumer ("DTC") channel, driven by full price sales, particularly in Retail. Our EMEA DTC business remains more variable, with our UK business in particular continuing to experience a challenging trading backdrop. Our APAC business continues to show good growth, with a particularly strong performance in South Korea driven by our well-established shoes category here.

Looking forward, the Autumn/Winter order books globally are healthy. The EMEA order book is up year-on-year, whilst the Americas order book is broadly in line year-on-year and importantly is based on a much wider product range than previously. As ever, our performance will be H2-weighted, particularly from a profit perspective.

We are focused on embedding our new consumer-first Levers for Growth strategy, which we outlined at our results on 5 June and which builds on the work undertaken in FY25 to stabilise the business. The strategy capitalises on the clear strengths of the business today and taps into the significant new markets and profit pools that are available to us. It is centred on engaging more consumers, driving more product purchase occasions, curating market-right distribution and simplifying the operating model. Further details on our early progress in these areas will be shared at our first half results in November.

Β 

Β 

Enquiries

Β 

Investors and analysts

Bethany Barnes, Director of Investor Relations +44 7825 187465 bethany.barnes@drmartens.com

Beth Fionda, Investor Relations Manager beth.fionda@drmartens.com

Β 

Press

Sodali & Co

Ludo Baynham-Herd

Oliver Banks drmartens@client.sodali.com

+44 207 250 1446

Β 

Β 

About Dr. Martens

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. "Docs" or "DMs" were originally produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over 60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and wholesale channels, and in addition to its world-renowned "1460" boot its product segments span shoes including the 1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and accessories. Further information can be found at https://www.drmartensplc.com/

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
TSTSSAFIUEISEDW
Date   Source Headline
8th Jun 202612:26 pmRNSHolding(s) in Company
5th Jun 202610:43 amRNSAdmission to Trading
2nd Jun 20269:00 amRNSDirector/PDMR Shareholding
2nd Jun 20269:00 amRNSAnnual Financial Report
2nd Jun 20268:22 amRNSTotal Voting Rights
27th May 20267:00 amRNSDirectorate change
19th May 20267:00 amRNSEBT Share Purchase
19th May 20267:00 amRNSFY26 Results
14th May 20268:53 amRNSDirector/PDMR Shareholding
1st May 20267:00 amRNSHolding(s) in Company
30th Apr 20268:31 amRNSTotal Voting Rights
29th Apr 20267:00 amRNSHolding(s) in Company
16th Apr 20267:00 amRNSDirector/PDMR Shareholding
15th Apr 20269:50 amRNSDirector/PDMR Shareholding
10th Apr 20261:46 pmRNSDirector/PDMR Shareholding
8th Apr 20267:00 amRNS-RAppointment of Market General Managers
31st Mar 20269:53 amRNSTotal Voting Rights
20th Mar 20267:00 amRNSHolding(s) in Company
13th Mar 20262:03 pmRNSDirector/PDMR Shareholding
27th Feb 202611:04 amRNSTotal Voting Rights
13th Feb 202610:49 amRNSDirector/PDMR Shareholding
30th Jan 202611:15 amRNSTotal Voting Rights
29th Jan 20267:00 amRNSEBT Share Purchase
27th Jan 20267:00 amRNSHolding(s) in Company
27th Jan 20267:00 amRNSQ3 FY26 Trading Statement
15th Jan 20269:24 amRNSDirector/PDMR Shareholding
31st Dec 202511:11 amRNSTotal Voting Rights
31st Dec 202511:11 amRNSTotal Voting Rights
12th Dec 20253:00 pmRNSDirector/PDMR Shareholding
12th Dec 20257:00 amRNSDirector/PDMR Shareholding
8th Dec 20257:00 amRNSDirector/PDMR Shareholding
1st Dec 202512:35 pmRNSBlock listing Interim Review
28th Nov 202511:58 amRNSTotal Voting Rights
25th Nov 20257:00 amRNSHolding(s) in Company
20th Nov 20257:00 amRNSH1 FY26 Results
12th Nov 20252:13 pmRNSDirector/PDMR Shareholding
31st Oct 20252:37 pmRNSTotal Voting Rights
21st Oct 20256:16 pmRNSHolding(s) in Company
20th Oct 20254:06 pmRNSHolding(s) in Company
16th Oct 20252:12 pmRNSDirector/PDMR Shareholding
14th Oct 202511:51 amRNSDirector/PDMR Shareholding
10th Oct 20257:00 amRNSAppointment of joint corporate broker
9th Oct 20251:53 pmRNSDirector/PDMR Shareholding
2nd Oct 20254:20 pmRNSTotal Voting Rights
2nd Oct 20257:00 amRNS-RUAE distribution partnership and LATAM expansion
16th Sep 202511:55 amRNSDirector/PDMR Shareholding
16th Sep 20257:00 amRNSHolding(s) in Company
2nd Sep 20259:30 amRNSDirector/PCA Shareholding
29th Aug 20254:22 pmRNSTotal Voting Rights
12th Aug 20253:17 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.